Rescue policy for discarded liver grafts: a single-centre experience of transplanting livers ‘that nobody wants’  by McCormack, Lucas et al.
ORIGINAL ARTICLE
Rescue policy for discarded liver grafts: a single-centre experience
of transplanting livers ‘that nobody wants’
Lucas McCormack1, Emilio Quiñonez1, María Martha Ríos2, Pablo Capitanich1, Nicolás Goldaracena1,
Javier Kerman Cabo1, Margarita Anders3, Javier Osatnik4, Pablo Comignani4, Norberto Mezzadri1 and
Ricardo Cesar Mastai3
1Department of General Surgery, Hospital Alemán of Buenos Aires, Buenos Aires, Argentina, 2Instituto Nacional Central Único Coordinador de Ablación e
Implante (Unique National Institute for Coordination of Ablation and Transplantation, INCUCAI), Buenos Aires, Argentina, 3Hepatology Service and 4Intensive
Care Unit, Hospital Alemán of Buenos Aires, Buenos Aires, Argentina
Abstracthpb_193 523..530
Background: There is a worldwide need to expand the donor liver pool. We report a consecutive series
of elective candidates for liver transplantation (LT) who received ‘livers that nobody wants’ (LNWs) in
Argentina.
Methods: Between 2006 and 2009, outcomes for patients who received LNWs were analysed and
compared with outcomes for a control group. To be defined as an LNW, an organ is required to fulfil two
criteria. Firstly, each liver must be officially offered and refused more than 30 times; secondly, the liver
must be refused by at least 50% of the LT programmes in our country before our programme can accept
it. Principal endpoints were primary graft non-function (PNF), mortality, and graft and patient survival.
Results: We transplanted 26 LNWs that had been discarded by a median of 12 centres. A total of 2666
reasons for refusal had been registered. These included poor donor status (n = 1980), followed by LT
centre (n = 398) or recipient (n = 288) conditions. Incidences of PNF (3.8% vs. 4.0%), in-hospital mortality
(3.8% vs. 8.0%), 1-year patient (84% vs. 84%) and graft (84% vs. 80%) survival were equal in the LNW
and control groups.
Conclusions: Transplantable livers are unnecessarily discarded by the transplant community. External
and internal supervision of the activity of each LT programme is urgently needed to guarantee high
standards of excellence.
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Introduction
Shortage of liver grafts accounts for the principal limitation of
liver transplantation (LT). Many surgical techniques have been
developed to minimize the effects of this deficit, including
reduced-size LT, single or dual graft live-donor LT, splitting a
cadaveric organ for two recipients, and domino transplantation.
In consequence to the dramatic reduction in the number of
live-donor grafts available in developed countries, many trans-
plant programmes have been driven to venture further into inno-
vative strategies, such as those involving the use of donors after
cardiac death, severe steatotic liver grafts or organs from so-called
‘expanded criteria donors’ (ECDs), as well as extracorporeal liver
perfusion systems for rescuing marginal liver grafts.1–5
The use of marginal liver grafts has been extensively discussed in
the literature.3,6–8 However, amajor concern in the transplant com-
munity refers to how we can safely relax deceased donor selection
criteria without compromising patient safety.9–11 In Europe, the
Essen group successfully transplanted 10 ‘livers that nobody
wants’ (LNWs) outwith the Model for End-stage Liver Disease
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(MELD)-based allocation system, which defines LNWs as livers
discarded by at least three transplant centres before their final
acceptance.12 In Argentina, LT activity was initiated over two
decades ago and a MELD-based allocation system was adopted in
2005 for patients listed for LT. In 2006 we initiated our new LT
programmeonwhich, forced by loworgan donation rates and high
mortality on the national waiting list, we decided to adopt an
aggressive policy in accepting livers from ECDs for patients listed
in our programme. Using a stricter and stronger definition of
LNW,weherein report our initial experience of transplanting these
otherwise discarded liver grafts allocated using the MELD system.
Materials and methods
Between August 2006 and April 2009, all patients who received
LNW transplants were included in the rescued livers group and
compared with a control group using a prospectively collected
database. To be defined as a ‘liver that nobody wants’, the organ
was required to fulfil two major criteria. Firstly, each liver must
have been officially offered and refused at least 30 times prior to
our final acceptance. In other words, a liver that had been dis-
carded by others was finally accepted by us for an elective candi-
date whose position on the national waiting list was later than
30th. The second criterion required the liver to have been refused
by more than half the active LT programmes in Argentina (i.e.
more than eight LT programmes). This study includes only
patients with a minimum follow-up time of 6 months after LT.
During the 32 months of the study period, 67 consecutive
LTs were performed in our programme. A consecutive series of
patients who were electively transplanted with a primary full-size
liver were included in this study (n = 51). In order to analyse a
homogeneous cohort of patients, the following conditions were
excluded: retransplantation (n = 3); emergency LT (n = 7); split-
liver transplantation (n = 2), and simultaneous kidney and LT
(n = 4). As a control group we used a consecutive series of patients
who underwent elective transplantation during the same period,
but whose initial positions on the waiting list at the time of liver
allocation were prior to 30th. Thus, this group included patients
who were more ill and who were better ranked on the national
waiting list as a result of their higher MELD scores.
Primary endpoints were primary non-function of the graft
(PNF), mortality, and graft and patient survival. Primary non-
function of the graft was defined as death or retransplantation
within 7 days following LT in the absence of any vascular prob-
lems. Secondary endpoints were secondary graft non-function
(i.e. vascular complications leading to graft loss within 7 days of
LT), primary dysfunction of the graft (PDF), hospital stay and
major postoperative complication rate. Primary dysfunction of
the graft was assumed when a peak AST (aspartate amino-
transferase) level >1.500 IU/l and a prothrombin time 50%
co-occurred within the first week.13,14
We analysed national official data from the Instituto Nacional
Central Único Coordinador de Ablación e Implante (Unique
National Institute for Coordination of Ablation and Transplan-
tation, INCUCAI) to assess procurement and transplantation
activity during the study period.We also collected from the official
national registry data on the reasons given by transplant centres
for refusing liver grafts.
Donor data
Organ procurement was performed as described elsewhere with
aortic and portal perfusion using University of Wisconsin preser-
vation solution (Viaspan™; DuPont Pharma, Wilmington, DE,
USA).15 In agreement with others,13,16–18 the following expanded
criteria for donors were identified: cardiac arrest for >15 min or
prolonged hypotensive episodes of <60 mmHg for >1 h; donor
age >55 years, positive hepatitis B virus (HBV) infection; high
vasopressor drug requirement (dopamine dose >10 mg/kg/min
or any doses of other amines); hypernatraemia >155 mEq/l; pro-
longed intensive care unit (ICU) stay (5 days with mechanic
ventilation); nosocomial infection (identified by positive blood
cultures or pneumonia); elevated liver transaminases (AST
>170 IU/l or ALT [alanine aminotransferase] >140 IU/l), and
prolonged cold ischaemia time (>12 h). Additionally, the body
mass index (BMI) of each donor was assessed. Donor obesity was
defined by a BMI 30 kg/m2.
Liver graft data
Pre-transplant donor graft biopsies were selectively performed in
the presence of any macroscopic or sonographic sign of steatosis
or fibrosis. Such livers were accepted only after histological evalu-
ation of the donor biopsy. After liver graft reperfusion, a core
needle biopsy was systematically performed in each recipient. His-
tological evaluation was performed to assess steatosis and fibrosis
using haematoxylin and eosin-stained sections of formalin-fixed,
paraffin-embedded liver tissue.Mild (<30%),moderate (30–60%)
and severe (>60%) steatosis were defined according to the per-
centage of the total amount of mixed fat droplets in the biopsy.
Liver fibrosis was quantified according to METAVIR score.19
Recipient data
All recipients were informed in detail about our policy of
accepting ECD grafts. Each LT recipient signed written informed
consent before surgery. All transplants were performed without
veno–venous bypass, as previously described.15 The following
recipient data were collected: age; underlying liver disease; MELD
score; BMI; recipient status on the waiting list (elective, emer-
gency); time on the waiting list; transfusion requirements, and
operative time.
Postoperative outcome
Liver function was evaluated clinically and through biochemical
parameters such as AST, ALT, bilirubin and prothrombin time
measured daily during the first week. Liver graft vascular patency
was evaluated by echo-Doppler ultrasound during the first day
and when clinically indicated. Major complications included
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complications of grades 3–5 (i.e. requiring surgical intervention
or ICU admission or causing death, respectively) according to a
validated classification system for postoperative complications.20
After discharge, each patient was followed in the multidisciplinary
outpatient clinic.
Statistical analysis
Summary data are presented as median (range). Differences
between groups were tested by chi-squared test for categorical and
Mann–Whitney U-test for continuous variables. Graft failure was
defined by death, retransplantation, documented cirrhosis or
advanced fibrosis. All tests were two-tailed. Statistical significance
was indicated by P < 0.05. Calculations were performed using spss
Version 13.0 (SPSS, Inc., Chicago, IL, USA).
Results
Transplant activity and mortality on the waiting
list in Argentina
The national organ donation rate in 2008 was 13.6 per million
population (PMP). There was great variation among the country’s
24 regions or provinces, with rates ranging from 34.5 PMP in
Corrientes to as low as zero in Santiago del Estero and San Luis.
Sixteen centres performed LT during the study period, of which 13
were private and three were public hospitals. However, when
transplant activity in each centre was evaluated, we found that
only seven centres performed more than 20 LTs per year, one
centre performed 10–20 LTs andmost centres performed under 10
LTs per year (n = 8).
During the study period, 1772 patients were registered on
the national waiting list, of whom 161 were listed as emergency
patients and 1611 were listed as being in elective conditions. The
overall mortality rate on the waiting list was 14.6% (n = 258);
mortality among emergency patients was 25.5% (n = 41) and that
among elective patients was 13.5% (n = 217). Transplantation
activity included 684 deceased-donor and 63 live-donor LTs (54
in paediatric and nine in adult recipients). The overall median
waiting list time was 4 days (range 1–19 days) for emergency and
74 days (range 1–1224 days) for elective candidates.
Waiting list characteristics and transplant activity on
our LT programme
During the 32-month period, 108 patients were included on our
waiting list: of these, 67 patients were successfully transplanted,
one died during the operation, one with fulminant liver failure
recovered spontaneously, six (5.6%) died while on the waiting list
and 33 were still waiting for a deceased liver donor at the time of
writing.
A total of 75 liver offers were accepted by our LT team.Of these,
three livers were not harvested (two donors suffered cardiac arrest
before our procurement team arrived and one harvesting was
cancelled because the necessary flight was delayed by bad
weather), four donor livers were discarded after procurement (one
for incidental ovarian cancer, one for incidental kidney cancer and
two for more than three ECD factors in addition to severe steatosis
in the frozen liver biopsy) and one patient died on the operation
table during transplantation immediately before biliary recon-
struction as a result of massive pulmonary thromboembolism
(position on the waiting list: 17th; MELD score: 18). Thus, 67 of
75 (89.3%) deceased-donor livers were transplanted to patients
on our waiting list.
Characteristics of the LNW group: donor- and
graft-related risk factors
We accepted and subsequently transplanted 26 organs that quali-
fied as LNWs. The median recipient position on the national
waiting list of this group was 71 (range 31–432). All but one graft
had one or more clinical and/or histological risk factors for LT.
The only graft discarded by all without any ECD risk factors came
from a 14-year-old donor and was discarded for reasons of size
mismatch and/or logistical reasons. The other discarded grafts
had one (n = 3), two (n = 7), three (n = 13) and four (n = 2) risk
factors for LT (Table 1). Our database registered that the most
frequent relevant risk factors in LNWs were inherent to the clini-
cal characteristics of the donor and included advanced donor age,
hypernatraemia, prolonged ICU stay and cerebrovascular accident
as cause of donor death. Donor obesity and alcohol abuse were
Table 1 Donor history and relevant clinical and graft-related risk
factors in the ‘livers that nobody wants’ (LNW) group (n = 26)
LNW group
n (%)
Donor history and characteristics
Peripheral vascular diseasea 8 (30.7)
Donor obesity (30 kg/m2) 5 (19.2)
Alcohol abuse 3 (11.5)
Diabetes mellitus 2 (7.6)
Clinical donor risk factors
Cerebrovascular accident (cause of donor death) 18 (69.2)
Donor age >55 years 12 (46.1)
Hypernatraemia >155 mEq/l 11 (42.3)
Prolonged intensive care unit stay 7 (26.9)
High vasopressor drug requirement 6 (23.0)
Nosocomial infectionb 4 (15.3)
Cardiac arrest for >15 min or prolonged hypotension 3 (11.5)
Elevated liver transaminases 2 (7.6)
Positive viral infection (HBV) 1 (3.8)
Graft-related risk factors
Steatosis 30% 5 (19.2)
Prolonged warm ischaemia time 3 (11.5)
Prolonged cold ischaemia time 1 (3.8)
aHistory of vascular disease included arterial hypertension, myocardial
infarction or previous cerebrovascular accident
bReferred to positive blood cultures or pneumonia
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present in 19% and 11%, respectively. Almost 20% of LNWs had
moderate to severe steatosis on liver biopsy.
Official reasons for refusing livers
Collectively, the 26 rescued livers had been consecutively dis-
carded by 298 transplant centres (median per organ: 12 centres,
range 9–14) before we finally accepted them. A total of 2666
refusals were officially documented, most of which were related to
poor donor conditions, followed by reasons inherent to the LT
centre or recipient status (Table 2). The most frequent causes for
refusal were poor donor history, poor donor ICU condition and
the non-operability of an LT centre. The reasons related to LT
centre condition only included: non-operability of the LT pro-
gramme (n = 305); logistical reasons (n = 45); shortage of blood
products (n = 39), and the impossibility of performing a second
LT in parallel (n = 9).
Interestingly, when the arguments used to discard a liver were
carefully analysed, we observed that poor donor history, size mis-
match, poor recipient condition and the non-operability of an LT
programme were present in more than two-thirds of the liver
offers. Surprisingly, 19 livers were discarded (i.e. 19 patients lost
the chance to be transplanted) because of the non-operability of
one or more LT programmes during the study period.
Clinical status of recipients in the LNW and
control groups
Recipient characteristics such as age, gender, time on the waiting
list, diagnosis and the incidence of hepatocellular carcinoma in
the explanted liver were comparable between groups (Table 3). As
expected, the median position on the waiting list at the time of
liver allocation was 71 for patients receiving a rescued liver com-
pared with 18 for patients in the control group (P < 0.001). Also as
expected, the median recipient MELD score with and without the
addition of priority points for MELD exceptions was significantly
lower in patients receiving LNWs compared with the control
group. In addition, the presence of three or four donor risk factors
was more frequently observed in LNWs compared with control
group organs (53% vs. 24%; P = 0.03).
Operative data and transfusion requirements
A piggyback technique was used in only one procedure and the
standard technique with vena cava resection was applied in all
others. Transitory porto–caval shunt was not used in any patient.
A full-size liver was implanted in each recipient; no patients
required technical adaptation to avoid intraperitoneal high
pressure secondary to a mismatch in size between the donor
liver and the recipient’s abdominal cavity. Only three grafts had
Table 2 Reasons (n = 2666) for refusal of livers (n = 26) officially








Donor-related conditions 1980 (74.2)
Poor donor history 1229 (46) 20 (76.9)
Poor donor ICU condition 521 (19.5) 7 (26.9)
Prolonged cold ischaemia 136 (5.1) 6 (23.0)
Abnormal biochemistry 64 (2.4) 6 (23.0)
Positive HBV serology 30 (1.1) 1 (3.8)
LT centre-related conditions 398 (14.9)
Non-operability of the LT centre 305 (11.4) 19 (73.0)
Logistical reasons 45 (1.6) 4 (15.3)
Shortage of blood products 39 (1.4) 5 (19.2)
Simultaneous LT 9 (0.3) 7 (26.9)
Recipient-related conditions 288 (10.8)
Size mismatch 194 (7.2) 19 (73.0)
Poor recipient conditions 64 (2.4) 19 (73.0)
Immunological factors 21 (0.7) 11 (42.3)
Recipient death 9 (0.3) 9 (34.6)
ICU, intensive care unit; HBV, hepatitis B virus; LT, liver transplant
Table 3 Transplant-related characteristics of the ‘livers that nobody wants’ (LNW) (n = 26) and control (n = 25) groups
LNW group Control group P-value
Median recipient age, years (range) 60 (21–73) 56 (20–69) 0.68
Gender, male/female, n 13/13 19/6 0.10
Diagnosis (HCV/alcohol/other), n 8/8/10 8/7/10 0.97
Hepatocellular carcinoma, n (%) 7 (26.9) 7 (28) 0.89
Median time in our LT programme, days (range) 53 (1–696) 42 (1–788) 0.72
Median position on the waiting list (range) 71 (31–432) 18 (2–29) <0.001
Median MELD score (range) 13 (6–21) 18 (6–34) 0.02
Median corrected MELD score (range) 13 (6–21) 22 (7–34) <0.001
Donor risk factors (2 vs. 3–4 factors) 11/15 19/6 0.03
MELD scores were calculated at the time of transplantation with and without correction for patients with hepatocellular carcinoma according to the
United Network for Organ Sharing (UNOS)
HCV, hepatitis C virus; LT, liver transplant, MELD, Model for End-stage Liver Disease
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a prolonged cold ischaemia time and four had warm ischaemia
time >40 min. The median cold (350 min vs. 350 min) and warm
(40 min vs. 35 min) ischaemia time of the liver graft were equiva-
lent in the rescued and control livers (Table 4).
The median operation time was similar in both groups
(248 min in the LNW group vs. 255 min in the control group;
P = 0.14). Intraoperative red blood cell (RBC) transfusions were
needed in only 61% of the consecutive series. Half of the rescued
livers were transplanted without the need of intraoperative RBC
transfusions, compared with 28% in the control group, but this
difference was not statistically significant (P = 0.18). Intraopera-
tive requirements for RBC, fresh frozen plasma and platelets units
were similar in both groups.
Postoperative outcomes
Mechanical ventilation was stopped immediately after LT in the
operation room in 23.5% of cases (19% of LNW patients vs. 26%
of control cases; P = 0.68). Postoperative biochemical profiles in
each group were similar in terms of transaminase peaks, but
the bilirubin peak was significantly lower in the LNW group
compared with the control group (Table 5).
One patient in each group developed PNF in the absence of
vascular problems and finally died as a result of uncontrolled
sepsis on postoperative days 10 and 12 (PNF rate: 3.8% in the
LNW group vs. 4% in the control group; P = 0.48). No patient
in the series developed secondary graft non-function after LT.
The incidences of PDF (15.3% in the LNW group vs. 16% in the
Table 4 Intraoperative variables and transfusion requirement in the ‘livers that nobody wants’ (LNW) (n = 26) and control (n = 25) groups
LNW group Control group P-value
Cold ischaemia time, min, median (range) 350 (240–1180) 350 (270–780) 0.77
Warm ischaemia time, min, median (range) 40 (28–56) 35 (28–42) 0.06
Operative time, min, median (range) 248 (150–360) 255 (195–360) 0.14
RBC transfusion, units, median (range) 0 (0–5) 1 (0–4) 0.42
LT without RBC transfusion, n (%) 13 (50) 7 (28) 0.18
FFP transfusion, units, median (range) 8 (0–16) 8 (0–16) 0.95
Platelets transfusion, units, median (range) 0 (0–10) 2 (0–14) 0.92
RBC, red blood cells; LT, liver transplant; FFP, fresh frozen plasma
Table 5 Comparative analysis of intraoperative outcome and postoperative biochemical profile and outcome in the ‘livers that nobody wants’
(LNW) (n = 26) and control (n = 25) groups
LNW group Control group P-value
Intraoperative outcome
Extubation in the ORa, n (%) 5 (19.2) 7 (26.9) 0.68
Biochemical profileb
Peak total bilirubin, mg/ml, median (range) 3.5 (0.9–14) 6.1 (1.5–25) 0.01
Peak ALT, U/l, median (range) 590 (163–4890) 590 (163–4890) 0.20
Peak AST, U/l, median (range) 533 (162–2870) 895 (240–17600) 0.19
Peak AST > 1500 U/l, n (%) 5 (19.2) 6 (24) 0.94
Prothrombin time < 50%, n (%) 13 (50) 12 (48) 1.00
Primary delayed function, n (%) 4 (15.3) 4 (16) 0.74
Postoperative outcome
Primary non-function, n (%) 1 (3.8) 1 (4) 0.48
Renal failurec, n (%) 2 (7.6) 1 (4) 0.97
Major complications, n (%) 4 (15.3) 5 (20) 0.94
ICU stay, days, median (range) 3 (1–12) 2 (1–27) 0.58
Hospital stay, days, median (range) 8 (5–33) 8 (4–47) 0.64
30-day mortality, n (%) 1 (3.8) 2 (8.0) 0.97
1-year patient survival rate 84% 84% 0.74
1-year graft survival rate 84% 80% 0.94
aWithdrawal of mechanical ventilation in the operating room
bPeak serum transaminases and total bilirubin or lower prothrombin time within the first week after liver transplant
cRequiring haemodialysis or haemofiltration
OR, operating room; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit
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control group), major complications (15.3% in the LNW group
vs. 20% in the control group) and renal failure (7.6% in the LNW
group vs. 4% in the control group) after LT were equal in both
groups (Table 5). The median ICU (3 days vs. 2 days) and hospital
stay (8 days in both groups) did not differ significantly between
the two groups. Although the 30-day mortality rate was lower in
the LNW group (3.8% vs. 8.0%; P = 0.97), this difference was not
significant. One-year rates for patient (84% vs. 84%) and graft
(84% vs. 80%) survival after LT were comparable in the LNW and
control groups.
Discussion
The scarcity of organs for LT is the most important factor leading
to the deaths of patients on LT waiting lists worldwide. In this
setting, we demonstrated that many usable livers are continuously
discarded by many LT centres. Our policy of using LNWs yielded
a reduction in time on the waiting list, very low waiting list mor-
tality and no drop-out from the waiting list arising from tumour
progression. Although most of the livers had been discarded by
others for reasons of unacceptable donor status, many refusals
were based on LT centre-related conditions, regardless of the
quality of the liver graft or the condition of the recipient. It is
interesting that we obtained postoperative outcomes and 1-year
graft and patient survival rates for transplants of ‘undesirable’
livers into recipients with low MELD scores similar to those
obtained in our consecutive series of the most ill patients who
received competitive organs allocated under the MELD system.
An ECD graft was recently defined as a liver with an increased
incidence of poor graft function, graft failure or transmission
of a donor-derived disease.7 However, this definition remains
subjective and the criteria for accepting a liver vary from country
to country and from centre to centre and sometimes depend on
whether or not the surgeon on call receives the offer of the liver.
In order to properly assess the outcomes of this series of LNW
LTs, we must first clarify whether the livers came from ECDs or
whether their acceptance was precluded by only recipient- or LT
centre-related conditions. Therefore, we carefully revised all ECD
risk factors affecting each of the LNWs and demonstrated that
the quality of the rescued livers was significantly impaired. As a
majority of these livers had three or four risk factors, we specu-
lated that many surgeons discarded the organs because of the
cumulative effect of these risk factors.14 As expected, the official
reasonmost frequently given by a centre for turning down an offer
of a liver in this series of LNWs was related to inadequate donor
condition. Unfortunately, our national centralized database failed
to provide interesting information regarding the surrogate donor-
related variables motivating each liver refusal. For example, the
exact abnormality in the donor biochemistry or the objective
variable that led the centre to assume a ‘poor ICU donor condi-
tion’ or ‘poor donor history’ could not be explored.
The most frequent argument used to discard a liver offer was
‘poor donor history’. By contrast, our aggressive policy mini-
mized the weight of previous donor history (e.g. diabetes,
peripheral vascular disease, donor obesity, alcohol abuse) and
relied mainly on the macroscopic aspect of the liver as assessed
by an experienced surgeon during harvesting or in the fresh
frozen biopsy as a definitive objective variable.1 We consider that
a donor history of alcohol abuse and donor obesity are unaccept-
able reasons for refusing a liver. These two conditions can even-
tually, but do not always, impair liver graft quality. However,
when dealing with ECD grafts, some conditions need to be care-
fully addressed: harvesting should be performed by experienced
surgeons; recipient surgery should be carried out with a meticu-
lous surgical technique and minimum blood loss, and maximum
efforts should be made to reduce the cold and warm ischaemic
time of the graft. Only with this strategy did we obtain postop-
erative graft outcomes similar to those achieved in the control
group.
Ongoing efforts aim to clarify how to optimize the matching of
donors with recipients.10,21 Initially,most centres advocated adher-
ing to the notion that ECD organs should be offered only to
candidates with extended indications of hepatocellular carci-
noma.12 However, it is now thought that ECD livers may be safely
directed to candidates with low MELD scores because healthier
recipients may better tolerate a poor initial function of the liver
graft or major postoperative complications.9,22,23 In Argentina, the
MELD-based allocation system was adopted in 2005 for patients
requiring LT. Unfortunately, some clinical conditions, such as
severe encephalopathy, hyponatraemia, refractory ascites, intrac-
table pruritus or recurrent bacterial cholangitis, lead to a dimin-
ished quality of life but are not relevant under the MELD
allocation policy.24–26 For these patients who require LT but who
are underestimated by the MELD system, these ‘undesirable’
organs may represent a valuable source of liver graft. Our strategy
was to simply direct these ‘unwanted’ livers to the candidates on
our waiting list whom we considered would benefit most from LT,
regardless of the MELD score calculated at the time of the liver
offer. Using this allocation strategy for these ECD livers, we
achieved postoperative outcomes and graft and patient survival
rates similar to those achieved with higher ranked patients trans-
planted with better organs. Further investigation might define
how we can improve transplant benefit to avoid futile LT under
the MELD system.
Previous European data have indicated that busy centres
(i.e. more than 35 LTs/year) are less selective in their decisions on
whether or not to accept a liver compared with lower-volume
centres.27 However, we demonstrated that this rule does not neces-
sarily apply inother countries.OurLNWgroup represented almost
half of our LT volume and we do not qualify as a high-volume
centre. Despite our surgical volume, and based on our commit-
ment to each patient enrolled on our programme, we decided to
accept LNWs and to evaluate the transplant benefit and the risk of
dying while waiting for a better organ on an individual basis.
This study raises the question of whether all LT centres should
become involved in accepting ECD offers. This policy has an
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inherent risk of cost-effectiveness and some important financial
issues need to be carefully addressed.22,23 Contractual reimburse-
ment agreements are not indexed by donor quality or the severity
of recipient disease, which results in a financial loss for the trans-
plant centre when post-transplant outcome is dismal.Our surgical
team failed to transplant 10% of the livers we accepted. Unfortu-
nately, health insurance does not usually cover the costs of recipi-
ent hospital admission or organ procurement if the liver is not
ultimately transplanted. For example, the cost of the preservation
solutions, transporting the liver team by ambulance or by plane
and the honoraries of the surgical team involved in the donor
surgery are not usually covered. It may be that centres that
perform fewer than 10 LTs per year should not economically
benefit from this policy. However, our surgical team considered
that procuring an ECD graft with the intent of saving a usable liver
is always beneficial from an ethical point of view when no other
options are available for a patient who may die while on the
waiting list. Institutional support and a comprehensive analysis of
the cost-effectiveness of the LT programme are paramount before
embarking on this aggressive approach. It may be advisable for
health insurance companies to share this policy in the future in
order to provide better support to experienced programmes that
opt to accept ECD grafts.
Finally, there are many non-medical reasons behind the dis-
carding of these livers and thus some political issues need to be
carefully addressed. Clearly, there is a wide variety in health care
systems, national regulations and transplant entities around the
world. In Latin America, the financial and political limitations
inherent to many developing countries in the region have nega-
tively impacted the growth of LT. The lack of adequate financial
coverage, education and organization are probably the main lim-
iting factors in many countries in the region. Curiously, in Argen-
tina the third most common reason for discarding a liver graft in
this series of LNWs was not related to either donor quality or
recipient status; it was, instead, related to transplant centre con-
ditions. We must state that during the study period we turned
down many offers of livers, but we did not prospectively collect
information regarding numbers and reasons. However, we can
confirm that although we refused some livers for donor- or
recipient-related reasons, we did not discard any organ as a con-
sequence of non-medical issues related to the LT centre. In Argen-
tina, the National Ministry of Health is in charge of overseeing
both private and public subsectors of the health care system and is
responsible for setting regulations, performing evaluations and
collecting statistics in this field. The INCUCAI is the national
entity controlling organ allocation and transplantation and must
guarantee equal access to LT in our country. Despite the great
medical effort expended to develop LT programmes in the
country, citing the shortage of blood products, logistical problems
or the non-operability of an LT as official reasons for turning
down a liver offer alerts us to the need for external monitoring
of the quality of health care in this field.28 National entities and
medical societies should focus on developing and implementing
specific regulations to ensure standards of excellence to provide
the highest quality of patient care in the area of LT.
In conclusion, we emphasize that transplantable livers are
unnecessarily discarded by the transplant community. Each trans-
plant centre should discuss on a case-by-case basis when to accept
an LNW to reduce the mortality and drop-out rates on the waiting
list. External and internal supervision of the activity of each LT
programme are urgently needed to guarantee a high standard of
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